Cancer Cachexia and Related Metabolic Dysfunction

  • Guilherme Wesley Peixoto da Fonseca
    Heart Institute (InCor), University of São Paulo Medical School, São Paulo SP 05403-900, Brazil
  • Jerneja Farkas
    Research Unit, General Hospital Murska Sobota, SI-9000 Murska Sobota, Slovenia
  • Eva Dora
    Division of Cardiology, General Hospital Murska Sobota, SI-9000 Murska Sobota, Slovenia
  • Stephan von Haehling
    Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), DE-37075 Goettingen, Germany
  • Mitja Lainscak
    Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia

説明

<jats:p>Cancer cachexia is a complex multifactorial syndrome marked by a continuous depletion of skeletal muscle mass associated, in some cases, with a reduction in fat mass. It is irreversible by nutritional support alone and affects up to 74% of patients with cancer—dependent on the underlying type of cancer—and is associated with physical function impairment, reduced response to cancer-related therapy, and higher mortality. Organs, like muscle, adipose tissue, and liver, play an important role in the progression of cancer cachexia by exacerbating the pro- and anti-inflammatory response initially activated by the tumor and the immune system of the host. Moreover, this metabolic dysfunction is produced by alterations in glucose, lipids, and protein metabolism that, when maintained chronically, may lead to the loss of skeletal muscle and adipose tissue. Although a couple of drugs have yielded positive results in increasing lean body mass with limited impact on physical function, a single therapy has not lead to effective treatment of this condition. Therefore, a multimodal intervention, including pharmacological agents, nutritional support, and physical exercise, may be a reasonable approach for future studies to better understand and prevent the wasting of body compartments in patients with cancer cachexia.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ